FDA lifts clinical hold on Hemispherx' Alferon LDO for flu prevention study
This article was originally published in Scrip
Executive Summary
Hemispherx Biopharma has announced that the US FDA has lifted a clinical hold on its Phase II study of Alferon LDO, or low-dose oral interferon alfa-n3 (human leukocyte derived), for the prevention and treatment of influenza.